Rhythm Pharmaceuticals (RYTM) PT Raised to $61 at Stifel
- Wall Street ends down as data spooks investors awaiting Fed report
- Roblox (RBLX) Lower as DAUs Fall Sequentially
- DraftKings (DKNG) Plunges as Hindenburg's Report Indicates Betting Company's Links to Black Market Operations
- Oracle (ORCL) Tops Q4 EPS by 23c
- U.S. retail sales take step back as spending pivots to services, trend remains strong
Stifel analyst Derek C. Archilia raised the price target on Rhythm Pharmaceuticals (NASDAQ: RYTM) to $61.00 (from $60.00) while maintaining a Buy rating.
You May Also Be Interested In
- Macquarie Upgrades Seek Ltd (SEK:AU) (SKLTF) to Outperform
- Lomon Billions Group Co Ltd (002601:CH) PT Raised to RMB53.70 at UBS
- HOYA Corporation (7741:JP) (HOCPF) PT Raised to JPY15,900 at JPMorgan
Create E-mail Alert Related CategoriesAnalyst PT Change
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!